Clinical Trial Update: Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of Nab Paclitaxel/Gemcitabine alone and with ACP-196 in metastatic pancreatic cancer was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• ACP-196 (acalabrutinib)
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-08-28